National Institute on Drug Abuse; Notice of Closed Meetings, 2540-2541 [2019-01413]
Download as PDF
<![CDATA[
2540
Federal Register / Vol. 84, No. 26 / Thursday, February 7, 2019 / Notices
National Cancer Institute, NIH, 9609 Medical
Center Drive, Room 7W242, Bethesda, MD
20892–9750, 240–276–6372, zouzhiq@
mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.392, Cancer Construction;
93.393, Cancer Cause and Prevention
Research; 93.394, Cancer Detection and
Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology
Research; 93.397, Cancer Centers Support;
93.398, Cancer Research Manpower; 93.399,
Cancer Control, National Institutes of Health,
HHS)
Dated: February 1, 2019.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2019–01347 Filed 2–6–19; 8:45 am]
BILLING CODE 4140–01–P
National Institutes of Health
Center for Scientific Review; Notice of
Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Endocrinology,
Metabolism, Nutrition and Reproductive
Sciences Integrated Review Group;
Integrative and Clinical Endocrinology and
Reproduction Study Section.
Date: February 21, 2019.
Time: 8:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: JW Marriott New Orleans, 614 Canal
Street, New Orleans, LA 70130.
Contact Person: Dianne Hardy, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 6175,
MSC 7892, Bethesda, MD 20892, 301–435–
1154, dianne.hardy@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
17:23 Feb 06, 2019
[FR Doc. 2019–01445 Filed 2–6–19; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
The inventions listed below
are owned by an agency of the U.S.
Government and are available for
licensing in the U.S. to achieve
expeditious commercialization of
results of federally-funded research and
development.
FOR FURTHER INFORMATION CONTACT:
Licensing information may be obtained
by emailing the indicated licensing
contact: Michael Shmilovich; National
Heart, Lung, and Blood, Office of
Technology Transfer and Development
Office of Technology Transfer, 31 Center
Drive Room 4A29, MSC2479, Bethesda,
MD 20892–2479; telephone: 301–402–
5579. A signed Confidential Disclosure
Agreement may be required to receive
any unpublished information.
SUPPLEMENTARY INFORMATION:
Technology description follows.
SUMMARY:
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
VerDate Sep<11>2014
Dated: February 2, 2019.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory
Committee Policy.
Jkt 247001
Potential Commercial Applications:
Inhibition of RIOK3 through genetic
manipulation or by using orally
administered kinase inhibitors will be a
novel and cost-effective treatment
strategy in beta-globinopathies.
Development Stage: The potential
clinical use of this novel invention will
depend on collaborating with interested
companies for efficiently inhibiting
RIOK3 through (1) designing lentiviral
vectors encoding shRNA to RIOK3, (2)
gene editing using endonucleases such
as CRISPR/Cas9 and (3) by developing
orally administered RIOK3 specific
kinase inhibitor drugs.
Inventors: Bjorg Gudmundsdottir,
Laxminath Tumburu, John Tisdale (all
of NHLBI).
Intellectual Property: HHS Reference
No. E–200–2018; U.S. Provisional Patent
Application 62/756,497 filed November
6, 2018.
Licensing Contact: Michael
Shmilovich, Esq., CLP; 301–435–5019;
shmilovm@mail.nih.gov.
Dated: December 26, 2018.
Michael A. Shmilovich,
Senior Licensing and Patenting Manager,
National Heart, Lung, and Blood Institute,
Office of Technology Transfer and
Development.
[FR Doc. 2019–01496 Filed 2–6–19; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Sickle Cell Anemia Treatment Through
RIOK3 Inhibition
National Institute on Drug Abuse;
Notice of Closed Meetings
Beta-globinopathy is a common
inherited single-gene disorder of betaglobin synthesis that results in an
abnormal structure of one globin chain
of the hemoglobin molecule. Common
hemoglobinopathies include sickle-cell
disease and beta-thalassemia. The
efficacy of bone marrow transplantation
is limited due to high cost and the
requirement for HLA-matched donors.
Increasing fetal hemoglobin expression
above a certain threshold is potentially
curative in the beta-globinopathies. The
inventors identified Rio-Kinase 3
(RIOK3) as a key negative regulator of
fetal hemoglobin expression in primary
human erythroid progenitor cells. Their
work shows that lentiviral mediated
shRNA knockdown of RIOK3 in primary
human erythroid progenitor cells
increased fetal hemoglobin expression
above 55% of total b-like globin
expression, thus, RIOK3 is a promising
novel therapeutic target to increase fetal
hemoglobin expression.
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
PO 00000
Frm 00054
Fmt 4703
Sfmt 4703
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel;
HEALing Communities Study: Developing
and Testing an Integrated Approach To
Address the Opioid Crisis (Data Coordinating
Center) (UM1-Clinical Trials Not Allowed).
Date: February 19–20, 2019.
Time: 7:30 p.m. to 5:00 p.m.
E:\FR\FM\07FEN1.SGM
07FEN1
Federal Register / Vol. 84, No. 26 / Thursday, February 7, 2019 / Notices
Agenda: To review and evaluate
cooperative agreement applications.
Place: Bethesda North Marriott Hotel &
Conference Center, 5701 Marinelli Road,
Bethesda, MD 20852.
Contact Person: Gerald L. McLaughlin,
Ph.D., Scientific Review Officer, Office of
Extramural Policy and Review, National
Institute on Drug Abuse, NIH, DHHS, 6001
Executive Blvd., Room 4238, MSC 9550,
Bethesda, MD 20892–9550, 301–827–5819,
gm145a@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos.: 93.279, Drug Abuse and
Addiction Research Programs, National
Institutes of Health, HHS)
Dated: February 1, 2019.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2019–01413 Filed 2–6–19; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Notice of
Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The contract proposals and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with contract
proposals, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Cancer
Institute Special Emphasis Panel; TEP–10:
SBIR Contract Review.
Date: March 12, 2019.
Time: 1:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate contract
proposals.
Place: National Cancer Institute, Shady
Grove, 9609 Medical Center Drive, Room
7W234, Rockville, MD 20850 (Telephone
Conference Call).
Contact Person: Adriana Stoica, Ph.D.
Scientific Review Officer, Resources and
Training Review Branch, Division of
Extramural Activities, National Cancer
Institute, NIH 9609 Medical Center Drive,
Room 7W234, Bethesda, MD 20892–9750,
240–276–6368 Stoicaa2@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.392, Cancer Construction;
93.393, Cancer Cause and Prevention
Research; 93.394, Cancer Detection and
Diagnosis Research; 93.395, Cancer
VerDate Sep<11>2014
17:23 Feb 06, 2019
Jkt 247001
Treatment Research; 93.396, Cancer Biology
Research; 93.397, Cancer Centers Support;
93.398, Cancer Research Manpower; 93.399,
Cancer Control, National Institutes of Health,
HHS)
Dated: February 1, 2019.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2019–01352 Filed 2–6–19; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of
Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Cellular
Aspects of Diabetes and Obesity.
Date: February 20, 2019.
Time: 1:00 p.m. to 2:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Marriott Wardman Park Washington
DC Hotel, 2660 Woodley Road NW,
Washington, DC 20008.
Contact Person: Elaine Sierra-Rivera, Ph.D.,
Scientific Review Officer, EMNR IRG, Center
for Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 6182,
MSC 7892, Bethesda, MD 20892, 301 435–
2514, riverase@csr.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
Dated: February 1, 2019.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2019–01407 Filed 2–6–19; 8:45 am]
BILLING CODE 4140–01–P
PO 00000
Frm 00055
Fmt 4703
Sfmt 4703
2541
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of
Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Biobehavioral and
Behavioral Processes Integrated Review
Group; Biobehavioral Mechanisms of
Emotion, Stress and Health Study Section.
Date: February 19–20, 2019.
Time: 8:00 a.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Le Meridien Delfina, 530 Pico
Boulevard, Santa Monica, CA 90405.
Contact Person: Benjamin Greenberg
Shapero, Ph.D., Scientific Review Officer,
Center for Scientific Review, National
Institutes of Health, 6701 Rockledge Drive,
Room 3182, Bethesda, MD 20892,
shaperobg@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
Dated: February 1, 2019.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2019–01417 Filed 2–6–19; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute on Drug Abuse;
Notice of Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
E:\FR\FM\07FEN1.SGM
07FEN1
]]>Agencies
[Federal Register Volume 84, Number 26 (Thursday, February 7, 2019)]
[Notices]
[Pages 2540-2541]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2019-01413]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute on Drug Abuse; Notice of Closed Meetings
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meetings.
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute on Drug Abuse Special
Emphasis Panel; HEALing Communities Study: Developing and Testing an
Integrated Approach To Address the Opioid Crisis (Data Coordinating
Center) (UM1-Clinical Trials Not Allowed).
Date: February 19-20, 2019.
Time: 7:30 p.m. to 5:00 p.m.
[[Page 2541]]
Agenda: To review and evaluate cooperative agreement
applications.
Place: Bethesda North Marriott Hotel & Conference Center, 5701
Marinelli Road, Bethesda, MD 20852.
Contact Person: Gerald L. McLaughlin, Ph.D., Scientific Review
Officer, Office of Extramural Policy and Review, National Institute
on Drug Abuse, NIH, DHHS, 6001 Executive Blvd., Room 4238, MSC 9550,
Bethesda, MD 20892-9550, 301-827-5819, gm145a@nih.gov.
(Catalogue of Federal Domestic Assistance Program Nos.: 93.279, Drug
Abuse and Addiction Research Programs, National Institutes of
Health, HHS)
Dated: February 1, 2019.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2019-01413 Filed 2-6-19; 8:45 am]
BILLING CODE 4140-01-P
